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Abstract A wild-type (wt) p53 gene characterizes thyroid
tumors, except for the rare anaplastic histotype. Because
p53 inactivation is a prerequisite for tumor development,
alterations of p53 regulators represent an alternative way
to impair p53 function. Indeed, murine double minute 2
(MDM2), the main p53 negative regulator, is overexpressed
in many tumor histotypes including those of the thyroid. A
new p53 regulator, MDM4 (a.k.a. MDMX or HDMX) an
analog of MDM2, represents a new oncogene although its
impact on tumor properties remains largely unexplored. We
estimated levels of MDM2, MDM4, and its variants,
MDM4-S (originally HDMX-S) and MDM4-211 (originally
HDMX211), in a group of 57 papillary thyroid carcinomas
(PTC), characterized by wt tumor protein 53, in comparison
to matched contra-lateral lobe normal tissue. Further, we
evaluated the association between expression levels of these
genes and the histopathological features of tumors. Quanti-
tative real-time polymerase chain reaction revealed a highly
significantdownregulation of MDM4 mRNAin tumor tissue
compared to control tissue (P<0.0001), a finding confirmed
by western blot on a subset of 20 tissue pairs. Moreover, the
tumor-to-normal ratio of MDM4 levels for each individual
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on the apoptotic response.was significantly lower in late tumor stages, suggesting a
specific downregulation of MDM4 expression with tumor
progression. In comparison, MDM2 messenger RNA
(mRNA) and protein levels were frequently upregulated
with no correlation with MDM4 levels. Lastly, we
frequently detected overexpression of MDM4-S mRNA
and presence of the aberrant form, MDM4-211 in this
tumor group. These findings indicate that MDM4 alter-
ations are a frequent event in PTC. It is worthy to note that
the significant downregulation of full-length MDM4 in
PTC reveals a novel status of this factor in human cancer
that counsels careful evaluation of its role in human
tumorigenesis and of its potential as therapeutic target.
Keywords MDM4.MDM2.Thyroidcarcinoma.
MDM4variants.p53
Introduction
The murine double minute (MDM) family members are key
regulators of levels and activity of the oncosuppressor p53
[1]. MDM2, acting as specific E3 ubiquitin ligase and as
transcriptional repressor, is the best known among them.
MDM2 overexpression has been observed in many human
tumors characterized by tumor protein 53 (TP53) wild-type
(wt) status, supporting the model of multiple means of p53
inactivation in tumor cells [2]. In recent years, another
member of the MDM family, MDM4 (also named MDMX)
has come into the limelight and its function in the
inactivation of p53 has been revealed by molecular and
genetic approaches [1, 3]. In particular, MDM4 can
negatively regulate p53-mediated cell cycle arrest, a role
that distinguishes its function from that of MDM2, more
related to the suppression of p53-mediated apoptotic
response [1, 3–5]. However, others have reported on the
antiproliferative and proapoptotic effect of MDM4 in the
presence of wild-type TP53 under conditions such as stress
[6, 7]. Studies aimed at characterizing the human MDM4
(also named HDMX) status in human tumors have shown
amplification of its locus in the presence of wild-type TP53
in breast cancers, glioblastoma, retinoblastoma, and soft-
tissue sarcomas [8–11], confirming that it may contribute to
p53 inactivation during tumorigenesis. The impact of
human MDM4 on tumor properties as well as its behavior
during tumor progression however still poorly explored.
In addition to the full-length (fl) protein, different splice
variants of MDM4 have been described, two of which
detected in human tumors. A short form named MDM4-S
(a.k.a. HDMX-S) was identified first [12]. This variant
derives from an alternative splicing that produces a
truncated protein, containing essentially the p53-binding
domain. It is a more potent inhibitor of p53 transcriptional
activity than wt MDM4 and although present in both
normal and tumor tissues, it is overexpressed specifically in
tumor samples [11, 12]. Recently, our group has character-
ized another MDM4-splicing form, HDMX211 (hereafter
named MDM4-211), in a thyroid tumor cell line and in
some lung cancers [13]. This form derives from an aberrant
splicing and produces a protein containing essentially the
RING finger COOH-terminus, where the MDM2 binding
site resides. As a consequence, this variant is able to
stabilize MDM2 protein levels, thus contributing to
inactivation of p53. These data, while underlying the
complexity of MDM4 expression in human tumors,
strongly encourage studies on the comparative analysis of
this protein and its derivative forms in human cancer.
Thyroid tumors represent over 90% of all endocrine
cancers and are characterized by different genetic alterations,
among which TP53 mutations are confined quite exclusively
to the infrequent anaplastic and poorly differentiated histo-
type [14]. According to current models of human carcino-
genesis that consider inactivation of the oncosuppressor p53,
a common feature of almost all tumors, MDM2 amplification
and/or overexpression have been reported in thyroid tumors
too [15–17]. However, the overall frequency of MDM2
overexpression is only about 30%, suggesting the existence
of other pathways of p53 inactivation.
The aim of our study has been to analyze papillary
thyroid carcinomas (PTC), the most frequent thyroid
cancer, for the presence of MDM4 and its derivative forms
to investigate alterations of these proteins in this tumor
histotype and correlate them with histopathological fea-
tures. In addition, we have analyzed MDM2 levels to assess
the potential relationship between alterations of the two
MDM family members. Our data have revealed the aberrant
presence of variants MDM4-S and MDM4-211 messenger
RNA (mRNA) in PTC as well as lack of correlation
between MDM4 and MDM2 mRNA levels. Of note, levels
of MDM4 mRNA were significantly downregulated in
tumor samples in comparison to normal counterparts, and
such downregulation appears significantly associated with
tumor stage.
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Tissue samples and patients
Fifty-seven papillary thyroid carcinomas and 57 matched
normal thyroid tissue samples from the contra-lateral lobe
(CTRL) of 57 patients were studied. In addition, to confirm
statistical analyses, 26 papillary thyroid carcinomas and
three normal thyroid tissues from independent individuals
were analyzed. All specimens were obtained from patients
undergoing surgery at the University of Perugia from 1997
to 2007. Before the surgical procedure, all patients signed
informed consent forms for collection of fresh thyroid
samples for genetic studies. All specimens were sampled
from the primary tumor at the time of surgery, snap frozen,
and stored at −80°C until use. Tumors containing at least
70% of tumor cells based on the hematoxylin–eosin
staining were selected. All normal thyroid tissue from the
contra-lateral lobe were histopathologically analyzed for the
presence of tumor. Available medical records of the patients
were consulted to gain information about the clinical
features of the disease and, when possible, the tumor stage
was defined according to the sixth edition of the “American
Joint Committee on Cancer” Cancer Staging Manual
(American Joint Committee on Cancer 2002) based on
pathological tumor–node–metastasis parameters and distin-
guishing patients in two groups: (1) patient age<45 years
(stage I and II), (2) patient age≥45 years (stage I, II, III, IV).
The total of 83 papillary thyroid carcinomas included 55
of the classic variant, 20 of the follicular variant, five of
other variants (tall cell, solid, diffuse sclerosing), and three
showing the coexistence of PTC histology with areas of
dedifferentiation. The mean period of follow-up was 45.8±
30.4 months.
Genetic analysis of TP53 mutation, BRAF mutations
and ret/PTC rearrangements
Analysis of the TP53 gene status was performed as follows:
e x o n s5 ,6 ,7 ,a n d8o fp53 gene were sequentially
amplified by polymerase chain reaction (PCR) assay with
the use of AmpliTaq Gold (Applied Biosystems) and
following primer sets: exon 5 sense: TTCCTCTTCCTA
CAGTACTC; exon 5 antisense: GCCCCAGCTGTTCAC;
exon 6 sense: ACTGATTGCTCTTAG; exon 6 antisense:
AGTTGCAAACCAGAC; exon 7 sense: AGTTGTGTT
ATCTCCTAG; exon 7 antisense: CAAGTGGCTCCTGAC;
exon 8 sense: TCCTATCCTGAGTAG; exon 8 antisense:
GTCCTGCTTGCTTAC. Purified PCR products were se-
quenced in both directions with the use of the BigDye
terminator Cycle sequencing Kit (version 1.1, Applied
Biosystems) and an ABI Genetic Analyzer (Model 3130,
Applied Biosystems). Sequence data were analyzed by
means of SeqScape software (version 2.1, Applied Bio-
systems) followed by manual review.
Search for mutations of BRAF was conducted by single-
stranded conformational polymorphism (SSCP) screening
of real-time (RT)-PCR products of exons 15, followed by
sequencing, as previously described [18]. Screening for ret/
PTC 1 and ret/PTC 3 rearrangements was performed by RT-
PCR using primers spanning the breakpoints, as previously
described [18].
Quantitative real-time PCR
Total RNA was extracted with Trizol™ (Invitrogen Corp.,
Carlsbad, CA, USA), according to the manufacturer’s
instructions. The expression of MDM2, MDM4, and
MDM4-211 in tumors and matching normal thyroid
samples was measured by quantitative real-time PCR
(qRT-PCR), based on TaqMan methodology, using the
ABI PRISM 7500 Sequence Detection System (Applied
Biosystems, Foster City, CA) according to Giglio et al.
[13]. Briefly, custom-designed TaqMan primers and probes
(Applied Biosystems) specific for MDM4, MDM2, and
MDM4-211 were used. Our results are expressed as relative
units of target mRNA, referred to a sample called calibrator,
chosen to represent 1× expression of the target gene. The
calibrator used was the lowest value in the tissue collection
under study. All analyzed samples express n-fold mRNA
relative to the calibrator. Each sample mRNA was normal-
ized relative to the β-actin mRNA. Predesigned TaqMan
primers and probe (Applied Biosystems) for the house-
keeping gene ß-actin were used. Each sample was treated
with deoxyribonuclease (DNase) I amplification grade
(Invitrogen) and tested before and after DNase treatment.
Comparative analysis of flMDM4 and MDM4-S was
driven by qRT-PCR according to Bartel et al., [11] using
specific probes and SYBR Master mix (Applied Biosys-
tems) with evaluation of dissociation curves. A MDM4-S-
to-flMDM4 ratio of >1.5 was considered indicative of
overexpressed MDM4-S.
Western blot analysis
Tumor and normal tissue pairs whose material was
sufficient for western blot analysis were selected. All
samples were homogenized with Tissue Lyser (Qiagen) and
western blots were performed according to Giglio et al. [13].
Briefly, samples were lysed in radio-immunoprecipitation
assay buffer (50 mM Tris–Cl pH 7.5, 150 mM NaCl, 1%
Nonidet P-40, 0.5% Na desoxicholate, 0.1% sodium
dodecyl sulfate (SDS), 1 mM ethylenediaminetetraacetic
acid) supplemented with a cocktail of protease inhibitors
(Boehringer). Whole lysates were boiled in SDS Laemnli
sample buffer, resolved by SDS-polyacrylamide gel elec-
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quently transferred to polyvinylidene fluoride membranes
(Millipore). After protein transfer, membranes were blocked
for 30 min with Tris-buffered saline containing 0.1%
Tween-20 and 5% nonfat dry milk and incubated with
specific antibodies. The following primary antibodies were
used: rabbit anti-MDM4 polyclonal antibody R1 (raised
against full-length MDM4 protein) and (Bethyl Laborato-
ries) mouse anti-MDM2 monoclonal antibody 2A10 and
monoclonal antibody Ab-1 (oncogene), mouse anti-α-
tubulin monoclonal antibody DM-1A (Sigma), and mouse
α-actin monoclonal antibody AC-40 (Sigma). MDM4 was
probed with both Bethyl and R1 antibodies, giving similar
results although, in comparison, the polyclonal antibody R1
was more sensitive. The homemade R1 antibody has been
raised using the entire MDM4 protein. Experiments of
epitope mapping by using MDM4-deletion mutants have
shown that R1 does not recognize the NH2-terminus of
MDM4.ItisthereforeunabletorecognizetheMDM4-Sform.
Statistical analysis
Statistic analysis was carried out using the Analyze-it
software for Microsoft Excel (Analyze-it Software, Ltd.).
Spearman rank correlations and Kendall rank correlation
(for measure of linear association) were used to evaluate the
correlation between not-normally-distributed variables. To
compare groups, we used the Wilcoxon Signed-Ranks test
for related samples (57 tumors vs. matched thyroid normal
tissues) and Mann–Whitney U test for independent samples
(83 tumors vs. 60 normal thyroid samples). A probability of
p<0.05 was considered as statistically significant. Intra-
individual variation was calculated by utilizing the T-to-N
ratio that derives from the ratio of corrected tumor (mRNA
or protein) levels to corrected normal tissue levels of
MDM4 and MDM2.
Results
Analysis of MDM4 and MDM2 levels in papillary thyroid
tumors
A group of 57 thyroid tumors samples and 57 matched
normal thyroid tissues from the CTRL were analyzed. All
tumors were of papillary histotype (PTC). The mean age of
the studied population was 49.4±16.81 (SD); the female
percentage was 72%. The histopathological features of the
57 tumors are shown in Table 1. Tumor stage was defined
according to the sixth edition of the “American Joint
Committee on Cancer.”
.
All samples were screened for the presence of TP53
mutations (limitedly to exons 5–8 where 80% of mutations
occur), BRAF mutations (by SSCP followed by sequence
analysis), and for ret/PTC 1 and ret/PTC 3 rearrangements
(by RT-PCR; Table 2). MDM4 and flMDM2 mRNA levels
were evaluated by qRT-PCR, using specific primers and
probes. MDM4 primers were chosen in a region not present
in the variant forms MDM4-S, HDMX-G [19] MDM4-211,
XALT1, and XALT2 [20] to amplify specifically the fl
Table 1 Histopathological
features of the 57 Papillary
Thyroid Tumors (PTC)
ND Not determined
Yes, n (%) No, n (%) ND, n (%)
BRAF mutation 35 (61) 20 (35) 2 (3)
Ret/PTC rearrangement 5 (9) 50 (88) 2 (3)
TP53 mutation 0 (0) 57 (100) 0
Extra-thyroidal invasion 15 (26) 41 (72) 1 (2)
Multifocality 24 (42) 32 (56) 1 (2)
Nodal metastasis 24 (42) 33 (58) 0
Distant metastasis 6 (10) 35 (62) 16 (28)
Tumor stage of patients <45 years (n=20)
I 15 (75) 0 5 (25)
II 0 (0) 15 (75) 5 (25)
Tumor stage of patients ≥45 years (n=37)
I 8 (22) 18 (48) 11 (30)
II 2 (5) 24 (65) 11 (30)
III 3 (8) 23 (62) 11 (30)
IV 13 (35) 13 (35) 11 (30)
Histology
Classic 38 (67) 19 (33) 0
Follicular 13 (23) 44 (77) 0
Other 4 (7) 53 (93) 0
Dedifferentiated 2 (3) 55 (97) 0
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J Mol Med (2008) 86:585–596 589product. Similarly, the chosen MDM2 primers do not
amplify the MDM2-A, MDM2-B, MDM2-C, MDM2-D,
and MDM2-E alternative spliced forms and most of the
aberrantly spliced forms [21].
MDM4 and MDM2 mRNA levels in normal tissues
followed a normal distribution according to Kurtosis
analysis (Fig. 1a,b). On the contrary, MDM4 and MDM2
values in tumor samples were not normally distributed (p<
0.0001; Fig. 1c,d). Comparative analysis by Wilcoxon
signed-ranks test for paired samples revealed a highly
significant difference in the distribution of MDM4 values
between tumor and CTRL groups (Wilcoxon’s W=1,385,
p<0.0001; Fig. 1e). Conversely, comparison of MDM2
values did not show significant difference (p=0.61;
Fig. 1f), in spite of the presence of four upper outliers in
the tumor sample set. There was no correlation between
MDM4 and MDM2 mRNA tumor levels indicating that the
alterations of the two transcripts are independent from one
another (data not shown).
To confirm the decrease of MDM4 mRNA levels in PTC
in comparison to CTRL, we analyzed these levels in an
additional 26 independent PTC and three normal thyroid
samples. Comparison of tumor and CTRL groups still
resulted in a highly significant correlation (Mann–Whitney
for independent samples U=634, p<0.0001) and confirmed
previous results of a strong downregulation of MDM4
expression in tumor samples. Indeed, study of prediction by
receive operator characteristics curves (ROC curves) indi-
cated that the use of MDM4 mRNA levels as potential
diagnostic test has a highly significant ability to discrimi-
nate between normal and tumor tissues (area under the
ROC 0.84, p<0.0001 Fig. 2).
To ascertain whether the decrease of MDM4 mRNA in
tumor samples results in decreased protein levels, we
analyzedwhole-cellextractsfrom20availablepairsoftumors
and CTRLs (Fig. 3). In 16 out of 20 pairs, the tumor-to-
CTRL ratio of densitometric values of the MDM4 protein
levels correlated significantly with the observed ratio of the
mRNA levels (Kendall tau=0.7, p=0.0002). Interestingly,
western blot confirmed the decrease of MDM4 mRNA in
tumor relative to normal tissue in seven samples, reinforcing
previous observations. Notably, in three samples (44, 27, and
33), we observed an increase of MDM4 proteins in tumor
compared to CTRL despite equal or even lower levels of
corresponding tumor mRNA relative to CTRL, indicating
MDM4 protein stabilization independent of transcription.
Western blot analysis revealed also the presence of an
additional species of about 58 kDa in some tumor samples
(Fig. 3, arrows). This band was recognized also by a mix of
three monoclonal antibodies to MDM4 (6B1A, 11F4D, and
12G11G, data not shown), suggesting it may be a MDM4
variant. However, its size does not correspond to any of the
MDM4 variant forms described so far.
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590 J Mol Med (2008) 86:585–596Further, western blot revealed frequent overexpression of
the MDM2 protein in tumors that did not show over-
expression of the mRNA (Fig. 3, samples marked by
section signs).
Analysis of intraindividual variation of MDM4 and MDM2
levels
Previous data were obtained by comparing tumors versus
CTRLs. We then analyzed the intraindividual variation of
MDM4 and MDM2 mRNA levels for each tumor (T) and
its matched CTRL (N) by calculating the relative ratio, T to
N. The range of MDM4 T-to-N ratios varied from 0.1 to 3.6
(Fig. 4a and Table 2). The majority of tumor samples
showed a decrease of MDM4 levels compared to the
corresponding CTRLs (29 out of 57 samples having a ratio
of <0.5), confirming the previously observed decrease of
tumor MDM4 expression at individual levels too. In other
tumor histotypes, amplification of MDM4 gene and over-
expression of the mRNA have been reported. In this PTC
group, MDM4 overexpression (as defined by a T-to-N ratio
of ≥5) was not detectable; in only two cases, the ratio of T
Fig. 1 a–d Frequency histo-
grams showing the distribution
of the mRNA levels of the
indicated genes in the indicated
sample groups. Relative units of
target mRNA are referred to a
sample called calibrator, chosen
to represent 1× expression of the
target gene. Each sample
mRNA was normalized relative
to the β-actin mRNA. The
superimposed line shows the
normal distribution curve. For
each distribution, the mean
(M)±standard deviation (SD)i s
shown. e, f Comparison of
MDM4 and MDM2 levels, re-
spectively, between control and
tumor samples. Each plot shows
graphically the central location
and scatter–dispersion of the
values of each group: the line
series shows parametric statis-
tics (mean and confidence inter-
val of mean) while the notched
box and whiskers show non-
parametric statistics (median,
confidence interval of median,
and interquartile range). Crosses
and circles indicate possible
outliers, between 1.5 and 3
interquartile range and over 3
interquartile range, respectively.
p value was calculated accord-
ing to Wilcoxon signed-ranks
test
J Mol Med (2008) 86:585–596 591to N showed a value of ≥2 (2 and 3.6, respectively). On the
contrary, comparison of MDM2 mRNA levels showed
tumor values twofold higher than matching CTRL in 11
samples, among which one had a ratio of >19, suggesting
an amplification event (Fig. 4b and Table 2). Moreover,
only six samples (10%) showed a ratio of <0.5, indicating
that downregulation of MDM2 levels in PTC tumor is a
rare event in comparison to that of MDM4. Notably, in two
of these tumors, western blot analysis did not confirm the
mRNA MDM2 decrease (Fig. 3; samples 35, 27).
Correlation of MDM4 and MDM2 with tumor
histopathological features
We then investigated whether tumor MDM4 and MDM2
mRNA levels as well as the T-to-N ratio varied according to
tumor properties by correlating them with the histopatho-
logical features of samples as reported in Table 1. First, we
examined their association with BRAF mutations and ret/
PTC rearrangements, two hallmarks of thyroid carcinogen-
esis. BRAF mutation were detected in 35 out of 57 patients,
ret/PTC rearrangements in 5 out of 57 (Table 2). All BRAF
mutations but one involved a heterozygous T>A trans-
version at nucleotide 1799, resulting in the prototypic
valine-to-glutamic-acid substitution at position 600
(BRAF
V600E). In one case, the in-frame insertion at position
1796 of an additional codon, coding for Valine, was
detected (BRAF
V599Ins). This was shown to be a “gain-of-
function” mutation in all super imposable to BRAF
V600E
[22]. No association was found between MDM4 and
MDM2 expression, BRAF mutations, and ret/PTC rear-
rangements suggesting that these oncogenic hits are
independent events. We then analyzed the correlation
between MDM4 or MDM2 expression with the other tumor
histopathological features. This revealed association of
MDM4 with multifocality of tumors: specifically, tumors
presenting as multifocal show higher values than non-
multifocal (Spearman rank correlation rs=0.29, p=0.032;
Fig. 5a, Table 3). This association was not evident when we
correlated multifocality with the MDM4 levels of matching
normal tissues (p=0.23), indicating that this tumor property
is not attributable to a patient predisposition given by
individual MDM4 expression levels but rather it is a
specific feature of tumor cells.
We also correlated MDM4 T-to-N ratio with tumor
features. We observed an even stronger association between
this parameter and multifocality (Spearman correlation
coefficient rs=0.32, p=0.01, Table 3), confirming previous
observations. Further, we found a significant correlation of
MDM4 T-to-N ratio with tumor stage (Spearman correla-
tion coefficient, rs=0.35 for n=41, p=0.02; Fig. 5b); in
particular, stage I tumors showed the highest ratio,
indicating downregulation of MDM4 levels in late-stage
tumors in comparison to early-stage ones (Table 3).
On the contrary, MDM2 levels as well as MDM2 T-to-N
ratio did not show correlation with any histopathological
parameter.
Characterization of MDM4 variants in thyroid tumors
We have analyzed the presence of the MDM4 variant
forms, MDM4-S and MDM4-211, in the same sample
group. So far, these are the only variant forms of MDM4
detected in human tumors. MDM4-S is a splicing variant
present both in normal and tumor tissues; however, in
tumor cells, MDM4-S is overexpressed and, as a conse-
quence, the ratio MDM4-S to flMDM4 is >1. At first, we
performed comparative analysis of flMDM4 and MDM4-S
by qRT-PCR in CTRL samples. In agreement with the
literature, we detected both transcripts in all samples with a
ratio MDM4-S to fl-MDM4 ranging from 0.09 to 0.79 with
only two samples showing values of 1.14 and 1.05 (data not
shown). On the basis of these results, we considered over-
expression as defined by a ratio of ≥1.5 The same analysis
in PTC detected MDM4-S in all but five samples; the
resulting MDM4-S-to-flMDM4 ratio was ≥1.5 in 20 out of
57 of tumors (35%; Table 2). The same percentage resulted
from the analysis of the additional group of 26 tumors (9
out of 26), in agreement with other reports [11]. Statistical
analysis did not reveal any significant association of MDM4-
S-to-flMDM4 ratio with the features described in Table 1.
The second variant form we investigated was MDM4-
211 (HDMX211), previously isolated from a thyroid tumor
cell line [13]. MDM4-211 mRNA was present in 7 out of
57 original tumor samples and in 8 out of 26 additional
Fig. 2 Receive operator characteristics curves for MDM4 levels
between normal and tumor samples, assessing variable MDM4 levels
as diagnostic test. The plot shows sensitivity of the test against
specificity. p value was 0.0001. For each decision threshold, the
percentage of tumor cases correctly identified as such (true positives)
against the percentage of normal cases incorrectly diagnosed as tumor
(false positives) is shown
592 J Mol Med (2008) 86:585–596samples analyzed with an overall frequency of 18% (Table 2
and data not shown). Its mRNA was not detected in any of
the CRTL samples, thus confirming its specific presence in
tumor tissue. In agreement with our previous reports [13],
western blot analysis of available tumor and CTRL samples
confirmed enhanced levels of the oncoprotein MDM2 in
tumors expressing MDM4-211 (Fig. 3, samples marked
by *). In our tumor set, the presence of MDM4-211 did not
Fig. 4 a, b Frequency histo-
grams showing the distribution
of the T-to-N ratios derived from
tumor–CTRL levels of the indi-
cated genes. The superimposed
line shows the normal distribu-
tion curve. For each distribution,
the mean±standard deviation is
shown
Fig. 3 Western blot of WCE
derived from 20 couples of
tumor (T) and matching control
(N). The values derive from the
ratio of densitometric value of
MDM4–actin, both at the pro-
tein and mRNA levels. Asterisks
mark tumor samples expressing
MDM4-211 mRNA; section
signs mark tumor samples
showing increased levels of
MDM2 protein with no in-
creased levels of the
corresponding mRNA. Arrows
mark a lower weight protein of
about 58 kDa, recognized by
different αMDM4 antibodies
J Mol Med (2008) 86:585–596 593correlate with any of the properties described in Table 1 nor
with the expression of the form MDM4-S, indicating that
the presence of these two variants is an independent event.
Some authors have hypothesized that the presence of
MDM4 variants may correlate with lower level of flMDM4
[11]. We therefore assessed the presence and expression of
MDM4-S and MDM4-211 in correlation with flMDM4 and
with the MDM4 T-to-N ratio. We observed no significant
correlation but rather a slight association between low
levels of both MDM4-S and flMDM4 (p=0.056).
Discussion
In this study, we have analyzed the expression of MDM4
and MDM2 mRNAs in a group of 57 papillary thyroid
tumors in comparison to matching normal tissues. We
observed that MDM4 levels are significantly lower in
tumor samples than in control. Specifically, tumor samples
expressing levels of MDM4 lower than matching control
are very frequent (51%) and this decrease in expression
appears to correlate significantly with higher tumor stages
(stage I in comparison to the other), indicating that it occurs
with tumor progression. These data led us to hypothesize
that a robust presence of MDM4 might exert an antagonis-
tic role in PTC evolution. To date, the majority of the
literature has reported amplification of MDM4 in the
presence of wt TP53 in different tumor histotypes [3],
partly in contrast with our data. However, a different status
of MDM4 in some cancer has also been reported. In a gene
profiling analysis, MDM4 downregulation was observed in
prostate tumors with poor prognosis in comparison to those
with good prognosis in agreement with the hypothesis that
MDM4 may be detrimental to tumor progression [23].
Moreover, two studies reported low levels of MDM4
protein in chronic myeloid leukemia tumor samples and in
tumor cell lines [24, 25]. It would be interesting to know
whether those cell lines have features resembling those of
advanced-stage tumors. Some authors have suggested that
low MDM4 expression levels may be correlated to the
presence of a mutated TP53 [11, 25]. However, lack of
detection of any of the most frequent mutation of TP53
gene in this PTC group does not support this hypothesis, at
least in this type of cancer. Similarly, in the prestate tumor
Fig. 5 a Vertical box-whisker plots showing MDM4 levels between
nonmultifocal (no) and multifocal (yes) tumors. Each plot shows
graphically the central location and scatter–dispersion of the values of
each group: the line series shows parametric statistics (mean and
confidence interval of mean) while the notched box and whiskers
show nonparametric statistics (median, confidence interval of median,
and interquartile range). Crosses and circles indicate possible outliers,
between 1.5 and 3 interquartile range and over 3 interquartile range,
respectively. p value was calculated according to Spearman test. b
Vertical box-whisker plots showing tumor–CTRL MDM4 mRNA
levels in stage 1 compared to other stages of tumors. Each plot shows
graphically the central location and scatter–dispersion of the values of
each group: the line series shows parametric statistics (mean and
confidence interval of mean) while the notched box and whiskers
show nonparametric statistics (median, confidence interval of median,
and interquartile range). Crosses and circles indicate possible outliers,
between 1.5 and 3 interquartile range and over 3 interquartile range,
respectively. p value was calculated according to Spearman test
Table 3 Summary of significant correlations of MDM4 and MDM4
T–N values with histopathological features
Multifocality Tumor Stage
Presence Absence I II–IV
n=24 n=32 n=23 n=18
MDM4 T–N
Mean±SD 0.9±0.76 0.56±0.43 0.81±0.54 0.51±0.43
Median±IQR 0.63±0.83 0.38±0.6 0.65±0.81 0.3±0.58
MDM4
Mean±SD 12.4±12.6 8.1±6.4 10.28±5.9 8.38±5.9
Median±IQR 8.74±8.7 6.19±5.1 8.85±5.44 5.7±8.0
594 J Mol Med (2008) 86:585–596study TP53 was found to be wild type by sequencing (A.
Farsetti, personal communication).
These data counteract the holistic view of MDM4 as a
p53 inactivation tool and suggest that its function may be
more complex than previously considered, at least in some
tissues. Thus far, molecular studies indicating MDM4
functions different from negative regulation of 53 have
provided evidence that MDM4 may display antiprolifer-
ative or proapoptotic activities, under stress conditions [6,
7]. Further, a recent work has shown for MDM4 a role in
suppressing tumorigenesis through the control of bipolar
mitosis [26]. Whether these mechanisms occur in PTC
remain to be elucidated.
In the analysis of tumor MDM4 expression levels, we
found that high levels of MDM4 are associated with
multifocal tumors. Different hypothesis have been postu-
lated to explain the origin of these tumors. Certainly,
multifocality is related to the high proliferative potential of
thyrocites. MDM4 has been reported as inhibitor of p53-
mediated growth arrest [1]; thus, it might be hypothesized
that the presence of MDM4 may predispose to multifocality
and tumor development, while a decrease in its expression
may confer an advantage to tumor progression. Interesting-
ly, one study has documented a statistically significant
association of MDM4 amplification with low-grade astro-
cytomas, thus supporting the hypothesis that high levels of
MDM4 may represent an early advantageous event for
tumor development [27]. Further, the association between
MDM4 levels and tumor multifocality is of particular
clinical relevance. Indeed, the possibility of early diagnosis
of tumor multifocality might allow discrimination between
partial or total thyroid gland ablation. The extension of this
type of analysis to a broader set of samples, including
benign lesions, should help to confirm these findings and to
investigate potential applications of this molecule in clinical
practice.
In addition, we have observed with high frequency the
aberrant presence of MDM4 alternatively spliced forms,
whose oncogenic activity has been assessed so far only in
vitro. In our analysis, the aberrant presence of these variants
did not correlate with any of the histopathological features.
In a study with primary sarcomas, the MDM4-S-to-
flMDM4 ratio correlated with enhanced cell proliferative
potential and decreased patient survival [11]. The high
incidence of patient survival in PTC (only three deaths in
our group, Table 2) does not allow to confirm this
association. For MDM4-211, this is the first frequency
report in a large group of tumor samples and indicates that
its presence is appreciable in PTC (18%). Interestingly,
these MDM4 variants forms show in vitro an even stronger
inhibitory activity toward p53 than the full-length protein.
Their presence may concur to modify the activity of
flMDM4, making more complex the assessment of its
function in tumor cells. It has to be mentioned that in many
PTC samples we observed the presence of a MDM4 minor
form whose nature is unclear, supporting the hypothesis
that MDM4 variants may concur to MDM4 oncogenic
functions.
Conversely, MDM2 mRNA levels were increased in
majority of tumor samples. In particular, we observed with
high frequency enhanced protein levels in tumor samples
that do not show enhanced mRNA levels. This is in accord
with previous reports and confirms that in thyroid tumors
MDM2 overexpression takes place frequently by mecha-
nisms other than enhanced transcription [28]. At least in
some of these samples, the simultaneous presence of
MDM4-211 variant may cause such upregulation. These
data further confirm the general view of the antagonistic
role of MDM2 toward the oncosuppressor p53. Finally, in
this study, we did not find any correlation between MDM2
and MDM4 mRNA levels, suggesting that the alterations
we observed occur independently from one another.
Overall, our results reveal that MDM4 alterations,
particularly the presence of its variant forms with p53-
inhibitory properties, are present at high frequency in PTC
confirming the general model of different ways of p53
inactivation in human tumors. However, our data represent
the first statistical report of a strongly significant down-
regulation of flMDM4 expression in cancer and particularly
in advanced-stage tumors, suggesting that this protein may
play additional roles besides p53 inactivation at least in
PTC. In view of the suggested strategies for abrogation of
MDM4 in human tumors [1, 3], our findings counsel
acquisition of more information on the molecular functions
of this protein in different human tumors in order to
carefully evaluate the application of such therapies.
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